• Clinical Trials |

Join our clinical trials

Results of 24 patients with median follow-up of 6 months have shown an average of 90% reduction in radiation of the prostate prescribed dose and significant reduction in any important radiation parameters at the rectum (healthy organ). No ProSpace associated side effects and with the expected balloon biodegradation.

BioProtect has completed preclinical studies and recently completed a multicenter pivotal study for the European market that included participant centers in the United States, Germany, Italy and Israel. The study was conducted in the following sites:

USA VCU Massey Cancer Center and VA Urology Medical Centers (Virginia)

VA Urology, Richmiond, Virginia.

Montefiore Medical Center, NYC, NY.

Germany University of Luebeck, University Hospital of Schleswig-Holstein (Luebeck)

Italy Padova University Hospital (Padova)

Israel  Sourasky Medical Center (Tel-Aviv)

Reduce & Minimize The effects of radiation
on surrounding tissue.

Testimonies

I would say that the device provides capability to significantly reduce the dose ...

Mitchell S. Anscher, MD, FACR, FACRO Florence and Hyman Meyers Professor and Chair Department of Radiation Oncology Virginia Commonwealth University School of Medicine Read More

© BioProtect 2010 | Site by EG Studio